Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for letermovir

  1. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.

    Technology appraisal guidance
    Published
    31 July 2019
    View recommendations

    Sections for TA591

  2. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868

    Awaiting development [GID-TA11361] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

    Technology appraisal guidance
    Published
    18 January 2023
    View recommendations

    Sections for TA860

  4. Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]

    In development [GID-TA11107] Expected publication date: TBC

    Technology appraisal guidance
    In development